BW Equities bullish on BLK
BW Equities Research has slapped a 75c 12-month price target on Blackham Resources (ASX:BLK), which represents a 54% uplift on its recent price.
The increased valuation come on the back of BLK recently putting out its Definitive Feasibility Study on its Matilda gold project.
That report, written for wholesale investors, confirmed production for this year with start-up of throughput and production likely to take place in the third quarter of this year.
According to the DFS, BLK now has a mining inventory of 45 million tonnes of ore at a grade of 3.2 grams per tonne for 4.7 million ounces.
The surer indicated category makes up 21Mt @ 3.4g/t for 2.3Moz.
An extra 2.5 years was added to the project’s mine life from the project’s pre-feasibility study as well as a 44% increase in inventory.
At this stage it has a seven year mining inventory run planned, with the goal to produce 100,0000/oz per year.
When factoring in pre-production capital costs of around $32 million, BLK expects to hit around $234 million in cash flow and a net present value of $170 million.
The report’s author, Chris Bain, said the report’s price assumptions included a gold price of $1600/oz.
While the price of gold has been stronger in this in recent times, according to BLK’s PFS the price during the past five years was $1500/oz, but with forecasting notoriously difficult it is challenging to get a hard and fast reading on the gold price going forward.
Everything else about the project, however, is getting more solid as BLK approaches production according to Bain.
“Risks associated with the Matilda Gold Project are rapidly reducing as DFS work together with ongoing drilling progresses,” he wrote.
BW also projected revenue from the project, with Bain forecasting BLK to bag $117 million in the 2017 financial year – however forecasts continue to be estimates only.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.